Lonza Pharma & Biotech – Sarah joined Lonza in August 2017 to build and lead a new business unit aimed at growing and accelerating the company’s portfolio of in- and out-licensing programs. With a focus on new modalities such as mRNA, cell and gene therapy, bio conjugates, and end-to-end manufacturing, she is responsible for scouting new technology, as well as creating value from Lonza’s internal R&D. Sarah knows the innovation and finance landscape in pharma and biotech well having previously helped lead Sanofi’s external science and partnering programme. Prior to Sanofi, Sarah managed teams in several roles at Roche and AstraZeneca and has overseen M&A transactions, integrations, spinouts and global brand launches. At Roche she built and led the team that built M&A cases and led integrations, and took a Breakthrough oncology drug to FDA and EMA submission.